Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Verrica Pharmaceuticals

Nasdaq:VRCA
Snowflake Description

Excellent balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
VRCA
Nasdaq
$259M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Verrica Pharmaceuticals Inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The last earnings update was 26 days ago. More info.


Add to Portfolio Compare Print
  • Verrica Pharmaceuticals has significant price volatility in the past 3 months.
VRCA Share Price and Events
7 Day Returns
11.4%
NasdaqGM:VRCA
4.6%
US Pharmaceuticals
2.4%
US Market
1 Year Returns
0.6%
NasdaqGM:VRCA
-2%
US Pharmaceuticals
-10%
US Market
VRCA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Verrica Pharmaceuticals (VRCA) 11.4% -3.9% -30.9% 0.6% - -
US Pharmaceuticals 4.6% -3.1% -7.9% -2% 10% 5.4%
US Market 2.4% -11% -19.4% -10% 9.6% 21.1%
1 Year Return vs Industry and Market
  • VRCA outperformed the Pharmaceuticals industry which returned -2% over the past year.
  • VRCA outperformed the Market in United States of America which returned -10% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Verrica Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Verrica Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Verrica Pharmaceuticals.

NasdaqGM:VRCA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.1%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:VRCA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.65
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.646 (1 + (1- 21%) (0.07%))
0.763
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (0.8 * 5.44%)
6.09%

Discounted Cash Flow Calculation for NasdaqGM:VRCA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Verrica Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:VRCA DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.09%)
2020 -59.20 Analyst x1 -55.80
2021 -73.15 Analyst x2 -64.99
2022 -45.80 Analyst x2 -38.35
2023 -2.10 Analyst x2 -1.66
2024 40.00 Analyst x2 29.76
2025 66.85 Est @ 67.13% 46.88
2026 98.61 Est @ 47.51% 65.19
2027 131.93 Est @ 33.78% 82.20
2028 163.81 Est @ 24.17% 96.20
2029 192.38 Est @ 17.44% 106.49
Present value of next 10 years cash flows $265.00
NasdaqGM:VRCA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $192.38 × (1 + 1.74%) ÷ (6.09% – 1.74%)
$4,497.34
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $4,497.34 ÷ (1 + 6.09%)10
$2,489.60
NasdaqGM:VRCA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $265.00 + $2,489.60
$2,754.60
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,754.60 / 25.81
$106.71
NasdaqGM:VRCA Discount to Share Price
Calculation Result
Value per share (USD) From above. $106.71
Current discount Discount to share price of $10.05
= -1 x ($10.05 - $106.71) / $106.71
90.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Verrica Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is $10.05 vs Future cash flow value of $106.71
Current Discount Checks
For Verrica Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Verrica Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Verrica Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Verrica Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Verrica Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:VRCA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.13
NasdaqGM:VRCA Share Price ** NasdaqGM (2020-04-07) in USD $10.05
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 20.33x
United States of America Market PE Ratio Median Figure of 2,948 Publicly-Listed Companies 12.95x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Verrica Pharmaceuticals.

NasdaqGM:VRCA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:VRCA Share Price ÷ EPS (both in USD)

= 10.05 ÷ -1.13

-8.87x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Verrica Pharmaceuticals is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Verrica Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Verrica Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGM:VRCA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.87x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
50%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.91x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.92x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Verrica Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Verrica Pharmaceuticals's assets?
Raw Data
NasdaqGM:VRCA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $2.52
NasdaqGM:VRCA Share Price * NasdaqGM (2020-04-07) in USD $10.05
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 2.42x
United States of America Market PB Ratio Median Figure of 5,162 Publicly-Listed Companies 1.26x
NasdaqGM:VRCA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:VRCA Share Price ÷ Book Value per Share (both in USD)

= 10.05 ÷ 2.52

3.99x

* Primary Listing of Verrica Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Verrica Pharmaceuticals is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Verrica Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Verrica Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Verrica Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
50%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Verrica Pharmaceuticals expected to grow at an attractive rate?
  • Verrica Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Verrica Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare Verrica Pharmaceuticals's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:VRCA Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:VRCA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 50%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.3%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:VRCA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:VRCA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 258 84 4
2023-12-31 174 23 4
2022-12-31 90 -35 4
2021-12-31 45 -59 5
2020-12-31 8 -62 4
2020-04-08
NasdaqGM:VRCA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -27 -28
2019-09-30 -26 -28
2019-06-30 -24 -28
2019-03-31 -23 -26
2018-12-31 -18 -21
2018-09-30 -13 -20
2018-06-30 -9 -15
2018-03-31 -6 -11
2017-12-31 -5 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Verrica Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Verrica Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:VRCA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Verrica Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:VRCA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 2.77 5.10 -0.35 4.00
2023-12-31 0.91 3.00 -1.46 4.00
2022-12-31 -1.09 -0.65 -2.06 4.00
2021-12-31 -2.15 -1.04 -3.40 5.00
2020-12-31 -2.30 -2.16 -2.44 4.00
2020-04-08
NasdaqGM:VRCA Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.13
2019-09-30 -1.13
2019-06-30 -1.12
2019-03-31 -1.30
2018-12-31 -1.41
2018-09-30 -2.17
2018-06-30 -4.26
2018-03-31 -4.18
2017-12-31 -3.42

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Verrica Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Verrica Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Verrica Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Verrica Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Verrica Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Verrica Pharmaceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Verrica Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Verrica Pharmaceuticals's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Verrica Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Verrica Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:VRCA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -28.21 14.64 15.44
2019-09-30 -28.15 13.90 16.38
2019-06-30 -27.96 13.27 16.80
2019-03-31 -26.28 11.63 16.39
2018-12-31 -20.65 9.05 12.83
2018-09-30 -19.81 6.10 9.03
2018-06-30 -15.26 3.47 6.68
2018-03-31 -11.04 1.63 4.14
2017-12-31 -9.76 0.73 3.73
2016-12-31 -1.91 0.20 1.71

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Verrica Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Verrica Pharmaceuticals has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Verrica Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Verrica Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Verrica Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Verrica Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Verrica Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Verrica Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Verrica Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Verrica Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Verrica Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Verrica Pharmaceuticals Company Filings, last reported 3 months ago.

NasdaqGM:VRCA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 65.02 0.00 62.02
2019-09-30 71.65 0.00 71.08
2019-06-30 76.85 0.00 78.75
2019-03-31 82.76 0.00 83.28
2018-12-31 89.43 0.00 89.81
2018-09-30 96.35 0.00 96.98
2018-06-30 101.59 0.00 103.15
2018-03-31 27.75 0.01 27.49
2017-12-31 8.47 0.00 8.66
2016-12-31 0.13 0.04 0.53
  • Verrica Pharmaceuticals has no debt.
  • Verrica Pharmaceuticals currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Verrica Pharmaceuticals has sufficient cash runway for 2.2 years based on current free cash flow.
  • Verrica Pharmaceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 67.9% each year.
X
Financial health checks
We assess Verrica Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Verrica Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Verrica Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Verrica Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought $2,000 of Verrica Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Verrica Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Verrica Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:VRCA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.9%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1935 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:VRCA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Verrica Pharmaceuticals has not reported any payouts.
  • Unable to verify if Verrica Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Verrica Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Verrica Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Verrica Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Verrica Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Verrica Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Verrica Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Verrica Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ted White
COMPENSATION $1,441,189
AGE 54
TENURE AS CEO 2.3 years
CEO Bio

Mr. Ted White has been the President and Chief Executive Officer at Verrica Pharmaceuticals Inc. since December 2017 and has been its Director since May 2018. Mr. White served as the President and General Manager of Aqua Pharmaceuticals, LLC from January 2016 to August 23, 2017. Mr. White served as the Chief Operating Officer of Aqua Pharmaceuticals, LLC from February 2013 to January 2016. Mr. White served as a Vice President of Sales at Aqua Pharmaceuticals LLC. Mr. White joined Aqua following a highly successful sales career with Novartis Pharmaceutical Corporation where he held the position of Managing Director. During his 21-year career with Novartis, he led sales teams with new product launches and executed strategies and tactics for multiple billion dollar brands. In his most recent role, he managed six brands and a staff that included ten area sales managers, three associate directors, group practices and 120 sales specialists. Mr. White was recognized by PharmaVoice magazine in July 2010 as one of the top 100 inspirational leaders in the health sciences field. Mr. White holds a M.B.A. from St. Joseph’s University and a B.A. in General Arts from Villanova University.

CEO Compensation
  • Ted's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Ted's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Verrica Pharmaceuticals management team in years:

1.8
Average Tenure
54
Average Age
  • The average tenure for the Verrica Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Ted White

TITLE
President
COMPENSATION
$1M
AGE
54
TENURE
2.3 yrs

A. Davis

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
52
TENURE
0.5 yrs

Joe Bonaccorso

TITLE
Chief Commercial Officer
COMPENSATION
$1M
AGE
55
TENURE
2.2 yrs

Christopher Hayes

TITLE
Secretary & General Counsel
AGE
55
TENURE
1.6 yrs

Patrick Burnett

TITLE
Chief Medical Officer
AGE
47
TENURE
2 yrs

Eugene Scavola

TITLE
Executive Vice President of Technical Operations
TENURE
0.5 yrs
Board of Directors Tenure

Average tenure and age of the Verrica Pharmaceuticals board of directors in years:

1.9
Average Tenure
50.5
Average Age
  • The average tenure for the Verrica Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Paul Manning

TITLE
Chairman of the Board
AGE
63
TENURE
2.3 yrs

Ted White

TITLE
President
COMPENSATION
$1M
AGE
54
TENURE
1.9 yrs

Mark Prygocki

TITLE
Independent Director
COMPENSATION
$241K
AGE
52
TENURE
1.9 yrs

Gary Goldenberg

TITLE
Independent Director
COMPENSATION
$183K
AGE
42
TENURE
1.9 yrs

Matt Davidson

TITLE
Member of Scientific Advisory Board
COMPENSATION
$238K
AGE
33

Sean Stalfort

TITLE
Director
AGE
49
TENURE
4.3 yrs

Mark Lebwohl

TITLE
Member of Scientific Advisory Board

Steven Cohen

TITLE
Member of Scientific Advisory Board

Elaine Siegfried

TITLE
Member of Scientific Advisory Board

Anthony Mancini

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
10. Oct 19 Buy Paul Manning Individual 08. Oct 19 10. Oct 19 20,886 $15.05 $300,280
X
Management checks
We assess Verrica Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Verrica Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Those Who Purchased Verrica Pharmaceuticals (NASDAQ:VRCA) Shares A Year Ago Have A 44% Loss To Show For It

Check out our latest analysis for Verrica Pharmaceuticals Verrica Pharmaceuticals didn't have any revenue in the last year, so it's fair to say it doesn't yet have a proven product (or at least not one people are paying for). … A Different Perspective Given that the market gained 6.2% in the last year, Verrica Pharmaceuticals shareholders might be miffed that they lost 44%. … You can find out about the insider purchases of Verrica Pharmaceuticals by clicking this link.

Simply Wall St -

Should You Take Comfort From Insider Transactions At Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)?

So shareholders might well want to know whether insiders have been buying or selling shares in Verrica Pharmaceuticals Inc. … In the last twelve months Verrica Pharmaceuticals insiders were buying shares, but not selling. … NasdaqGM:VRCA Recent Insider Trading, June 14th 2019 Verrica Pharmaceuticals is not the only stock that insiders are buying.

Simply Wall St -

Who Has Been Buying Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Shares?

We often see insiders buying up shares in companies that perform well over the long term. … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … The Last 12 Months Of Insider Transactions At Verrica Pharmaceuticals.

Simply Wall St -

How Many Insiders Bought Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Shares?

So we'll take a look at whether insiders have been buying or selling shares in Verrica Pharmaceuticals Inc. … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … Verrica Pharmaceuticals Insider Transactions Over The Last Year.

Simply Wall St -

Who Are The Top Investors In Verrica Pharmaceuticals Inc (NASDAQ:VRCA)?

If you want to know who really controls Verrica Pharmaceuticals Inc (NASDAQ:VRCA), then you'll have to look at the makeup of its share registry. … With a market capitalization of US$358m, Verrica Pharmaceuticals is a small cap stock, so it might not be well known by many institutional investors. … View our latest analysis for Verrica Pharmaceuticals

Simply Wall St -

Who Are The Top Investors In Verrica Pharmaceuticals Inc (NASDAQ:VRCA)?

In this article, I'm going to take a look at Verrica Pharmaceuticals Inc’s (NASDAQ:VRCA) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … The effect of an active institutional investor with a similar ownership as a passive pension-fund can be vastly different on a company's corporate governance and accountability to shareholders. … Therefore, it is beneficial for us to examine VRCA's ownership structure in more detail.

Simply Wall St -

Company Info

Description

Verrica Pharmaceuticals Inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company’s lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. It is also developing cantharidin-based product candidate, VP-103 for the treatment of plantar warts. The company was founded in 2013 and is headquartered in West Chester, Pennsylvania.

Details
Name: Verrica Pharmaceuticals Inc.
VRCA
Exchange: NasdaqGM
Founded: 2013
$259,435,654
25,814,493
Website: http://www.verrica.com
Address: Verrica Pharmaceuticals Inc.
10 North High Street,
Suite 200,
West Chester,
Pennsylvania, 19380,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM VRCA Common Stock Nasdaq Global Market US USD 15. Jun 2018
DB 1NE Common Stock Deutsche Boerse AG DE EUR 15. Jun 2018
Number of employees
Current staff
Staff numbers
17
Verrica Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 07:48
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/03/23
Last earnings filing: 2020/03/13
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.